CRO spécialisée en drug discovery, services précliniques et cliniques
 

Posters Upcyte

Affiches Scientifiques sur la Technologie upcyte®

CliniSciences présente une sélection d’affiches scientifiques réalisées par upcyte technologies GmbH ainsi que par nos collaborateurs et partenaires. Ces affiches mettent en évidence les applications de la technologie upcyte® dans les domaines de la prolifération des hépatocytes, du métabolisme, du criblage de toxicité, des cellules endothéliales sinusoïdales du foie, des modèles d’organoides et d’autres thématiques présentées lors de congrès majeurs (Eurotox, ISSX, SOT, GASL, etc.).

Affiches d’upcyte technologies GmbH

No. 1 : upcyte® hepatocytes – proliferating and metabolic competent human hepatocytes (Eurotox 2015)
No. 2 : Generation of proliferating human hepatocytes with enhanced CYP enzyme activities (ISSX 2015)
No. 3 : Toxicology testing using upcyte® hepatocytes (ISSX 2015)
No. 4 : Use of upcyte® hepatocytes to predict toxicological outcomes (SOT 2016)
No. 5 : Metabolic competent expandable upcyte® hepatocytes enable metabolism studies including CYP2D6 dependent pathways (SOT 2016)
No. 6 : Generation of proliferating human liver sinusoidal endothelial cells (ISSX 2016)
No. 7 : Liver organoid formation using differentiated human upcyte® cells (Dechema 3D 2016)
No. 9 : Characterization of proliferating hepatocytes as a model system for drug interaction studies and toxicity screenings (Eurotox 2016)
No. 10 : Generation of proliferating human liver sinusoidal endothelial cells (upcyte® LSECs) and upcyte® hepatocytes (Eurotox 2016)
No. 11 : Generation of expanded primary human cells in large quantities for cell-based screenings (SLAS 2017)
No. 12 : Generation of expanded primary hepatocytes in large quantities for for cell based toxicity & metabolism screenings (SLAS/SOT 2017)
No. 13 : Detection of cytokeratin 18 in proliferating, primary-like upcyte® hepatocytes to predict drug-induced hepatotoxicity (SOT 2017)
No. 14 : Use of upcyte® hepatocytes as a steatosis model on a multi-organ-chip (SOT 2017)
No. 15 : Generation of expanded primary human cells (upcyte®) in large quantities for cell-based screenings (European ISSX 2017)
No. 16 : Driving primary liver cells into proliferation (European ISSX 2017)
No. 17 : Generation of expanded primary hepatocytes for cell based toxicity and metabolism screenings (European ISSX & Gordon Conference 2017)
No. 18 : Generation of expanded primary cells for cell-based toxicity and metabolism screenings (Safety & Pharmacology 2017)
No. 19 : Generation of proliferating human liver sinusoidal endothelial cells (upcyte® LSECs) (GASL 2018)
No. 20 : Generation of expanded primary hepatocytes for cell based toxicity and metabolism screenings (GASL 2018)
No. 21 : Facilitated genotoxicity screenings in expanded human upcyte® keratinocytes (SOT 2018)
No. 22 : Expanded primary human liver sinusoidal endothelial cells as a tool to complement hepatotoxicity studies (SOT2018)
No. 23 : Generation of Expanded Primary Cells for Cell-Based Toxicity andMetabolismScreenings (SLAS 2018)
No. 24 : Hepatobiliary transporter expression and functional uptake of substrates in 2D sandwich cultures using upcyte® hepatocytes (veuillez consulter la publication)
No. 25 : Toxicity assays using expanded liver cells promote the reduction of animal use in pre-clinical research (Eurotox 2018)
No. 26 : Liver bud formation using human upcyte® cells (EUSAAT 2018)
No. 27 : Generation of proliferating mouse hepatocytes (upcyte® mouse hepatocytes) (ISSX 2019)
No. 28 : in vitro organoid model of the human liver sinusoid (Gordon Metabolism 2019)
No. 29 : Generation of Expanded Primary Cells for Cell-Based Toxicity and Metabolism Screenings (Eurotox 2019)
No. 30 : Expanded primary human liver sinusoidal endothelial cells (upcyte® as a tool to complement in vitro hepatic studies (GASL 2020)
No. 31 : Expanded primary human liver sinusoidal endothelial cells (upcyte® LSECs) as a tool for complex hepatotoxicity studies (SOT 2020)
No. 33 : Application poster: upcyte® hepatocytes for CYP induction studies

Affiches de nos clients et partenaires

Gaitantzi et al., Universitätsmedizin Mannheim (Mannheim, Allemagne) – BMP-9 modulates the hepatic responses to LPS (GASL 2020)
Hambruch et al., Phenex Pharmaceuticals (Heidelberg, Allemagne) – LXR inverse agonists demonstrate liver lipid lowering effects through multiple mechanisms in rodent models of NASH and in human hepatocytes (EASL 2017)
Kroener et al., Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology (Stuttgart, Allemagne) – a multi-level approach to investigate CYP2D6 dependent metabolism of clomiphene (ISSX 2017)
Maalouf et al., Indigo Biosciences (State College, PA, États-Unis) – Validating the gene expression of clinically relevant CYP450 enzymes and transporters in human upcyte® hepatocytes to develop an in vitro predictive tool for DDI (SOT 2017)
Schaefer et al., Boehringer Ingelheim (Biberach, Allemagne) – Metabolic Capability of Upcyte® Human Hepatocytes in Long-Term Sandwich Culture and Utility for Clearance Prediction (ISSX Korea 2016)
Schaefer et al. II, Boehringer Ingelheim (Biberach, Allemagne) – Comparison of Primary vs. Proliferative Human Hepatocytes in Long-Term Culture: Metabolic Capability and Usefulness for Clearance Prediction (ISSX Boston 2016)
Bauer et al., Tissuse GmbH (Berlin, Allemagne) – Towards a multi-organ-chip combining human liver, pancreatic islets, skeletal muscle and kidney equivalenst to study metabolic diseases

Intéressé(e) par les affiches upcyte® ou une collaboration ?

Contactez-nous pour obtenir plus d’informations, accéder aux affiches complètes ou discuter d’éventuelles collaborations et applications de la technologie upcyte®.

Contactez-nous à l’adresse tech@clinisciences.com

Nous contacter